10-K: NanoViricides FY25 10-K: Broad-Spectrum Drug Advances Amidst Funding Challenges

NanoViricides, Inc. reports progress in broad-spectrum antiviral drug NV-387's clinical development, including Phase Ia/Ib completion, but faces significant financial constraints and a going concern doubt.

Summary

• NanoViricides, Inc. (NNVC) is a clinical-stage biopharmaceutical company focused on developing nanoviricide drugs for viral infections.
• The company reported a net loss of approximately $9.47 million for the fiscal year ended June 30, 2025, an increase from $8.29 million in the prior year.
• Accumulated deficit reached approximately $148.84 million as of June 30, 2025.
• Cash and cash equivalents stood at approximately $1.56 million at June 30, 2025, with an additional $1.25 million raised through ATM sales post-period end (July 1 Sept 24, 2025).
• Management believes current resources, including a $3 million line of credit from Dr. Anil Diwan, are insufficient to fund operations for the next 12 months, raising substantial doubt about the company's ability to continue as a going concern.
• The lead drug candidate, NV-387, a broad-spectrum antiviral, successfully completed Phase Ia/Ib human clinical trials for safety and tolerability with no reported adverse events.
• NV-387 demonstrated strong antiviral activity in lethal animal models against Coronavirus, RSV, Influenza, Orthopoxvirus (Smallpox/MPox), and Measles.
• The company is planning two Phase II clinical trials for NV-387: one for MPox in the Democratic Republic of Congo (DRC) and another adaptive, basket-type trial for viral acute and severe-acute respiratory infections (ARI/SARI) in India.
• NV-387 has been formulated for multiple routes of administration, including oral syrup, oral gummies, injection, infusion, and inhalation.
• The company owns fully integrated facilities for drug development and cGMP-compatible manufacturing, valued at over $6.8 million post-depreciation.
• Intellectual property is based on exclusive licenses from TheraCour Pharma, Inc., a related party substantially owned by Dr. Anil Diwan, with patents extending to 2043 and beyond.
• The company is actively seeking non-dilutive funding (grants, contracts) and partnerships for further drug development and commercialization.

Sentiment

Score: 3

Explanation: While the company has achieved significant scientific milestones with NV-387's safety profile and broad-spectrum preclinical efficacy, and has integrated manufacturing capabilities, its financial position is precarious. The substantial doubt about its ability to continue as a going concern, increasing net losses, declining cash balance, and reliance on dilutive financing and related-party debt indicate high financial risk. Delays due to resource constraints further temper optimism despite promising drug candidates.

Positives

• Lead drug candidate NV-387 successfully completed Phase Ia/Ib human clinical trials with no drop-outs, no reported adverse events, and good tolerability even at highest doses, indicating a strong safety profile.
• NV-387 demonstrated broad-spectrum antiviral activity in lethal animal models against Coronavirus, RSV (complete cure in mice with no lung damage), Influenza (superior to three approved drugs), Orthopoxvirus (MPox/Smallpox, matched approved drug tecovirimat, combination was significantly better), and Measles (130% increase in survival lifespan).
• The company owns fully integrated facilities for drug design, discovery, chemical synthesis, antiviral evaluation, scale-up, cGMP-compatible manufacturing, formulation, filling, labeling, packaging, and analytical testing, which de-risks development and saves time/cost.
• NV-387 has been formulated for multiple routes of administration (oral syrup, oral gummies, injection, infusion, inhalation), offering versatility for various patient populations and disease severities.
• The company has a strong intellectual property portfolio through exclusive, worldwide licenses from TheraCour Pharma, Inc., with patents extending to 2043 and beyond.
• Preliminary approval obtained from ACOREP (DRC) Ethics Committee for Phase II MPox clinical trial.
• NV-387 is eligible for Orphan Drug Designation for MPox, Smallpox, and Measles, which offers benefits like PDUFA fee waivers, tax credits, and 7-year market exclusivity.
• The company has a $3 million line of credit from its founder, Dr. Anil Diwan, extended to March 31, 2027, which provides some financial flexibility.
• The company has engaged a consulting firm (Aagami, Inc.) to actively seek partnerships and out-licensing opportunities, with non-disclosure agreements already signed with potential collaborators.

Negatives

• The company is in the developmental stage with no products approved for commercial sale, no customers, and no revenues to date.
• Reported a net loss of approximately $9.47 million for the fiscal year ended June 30, 2025, an increase from $8.29 million in the prior year.
• Accumulated deficit reached approximately $148.84 million as of June 30, 2025.
• Cash and cash equivalents of $1.56 million at June 30, 2025, are insufficient to fund planned operations for at least 12 months, raising substantial doubt about the company's ability to continue as a going concern.
• The company relies heavily on equity-based financing and related-party debt, which can lead to significant shareholder dilution.
• Increased operating expenses, with R&D up by $112,000 to $5.55 million and G&A up by $964,000 to $4.04 million for FY2025.
• Interest income decreased from $271,773 in FY2024 to $124,828 in FY2025 due to lower cash balances.
• The second part of the NV-387 Phase Ia/Ib clinical trial for COVID-19 patients was canceled due to inability to find patients, indicating potential challenges in patient recruitment for specific indications.
• The RSV program priority was lowered from the prior annual report due to current fiscal limitations.
• The company is experiencing extreme staffing and financial constraints, which have already caused substantial delays and may continue to do so.
• Dependence on external collaborators and CROs for animal studies, regulatory affairs, and clinical trials introduces risks of delays and non-compliance.
• Significant related-party transactions, including licenses from TheraCour Pharma, Inc. (90% owned by Dr. Anil Diwan) and clinical trial management by Karveer Meditech Pvt. Ltd. (where Dr. Diwan is a passive investor), raise potential conflict of interest concerns.
• The company has limited experience in pharmaceutical drug development and budget estimates are not based on extensive experience, potentially leading to inaccuracies and cost overruns.

Risks

• The company is in the developmental stage and has no products approved for commercial sale, no generated revenue, and may never achieve profitability.
• The company will need to raise substantial additional capital in the future to fund operations and may be unable to raise such funds when needed and on acceptable terms.
• Due to the nature of the process involved in the development of pharmaceuticals, the company can provide no assurance of the successful and timely development of new drugs.
• The company must comply with significant and complex government regulations, which may delay or prevent the commercialization of drug candidates.
• The company can provide no assurance that drug candidates will obtain regulatory approval or that the results of clinical studies will be favorable.
• In the event that regulatory approvals are obtained, drug candidates will be subject to ongoing regulatory review; failing to comply with U.S. and foreign regulations could result in loss of approvals to market such drugs and would harm the business.
• Development of drug candidates requires significant research and development, which will lead to significant R&D costs that are uncertain and subject to fluctuation.
• The company has limited experience in conducting or supervising clinical trials and must outsource clinical trials, relying on third parties for compliance and performance.
• The company may be unable to attract or retain and motivate skilled personnel, which will delay product development programs and research and development efforts.
• The company has no sales or marketing personnel and relies on strategic collaborations for commercialization.
• The company's collaborative relationships with third parties could cause the company to expend significant resources and incur substantial business risk with no assurance of financial return.
• The company may be liable for damages caused by biological and hazardous materials used in R&D and manufacturing.
• The company depends on senior management, particularly Dr. Anil Diwan, and their loss or unavailability could put the company at a competitive disadvantage.
• Conflicts of interest exist among officers, directors, and stockholders due to Dr. Anil Diwan's ownership in TheraCour and KMPL.
• Anticipated contracts with U.S. government agencies for biodefense applications are subject to various federal contract requirements, unfavorable termination provisions, audits, and funding uncertainties.
• The biotechnology and biopharmaceutical industries are characterized by rapid technological developments and a high degree of competition from enterprises with more substantial resources.
• The successful development of biopharmaceuticals is highly uncertain, and products may fail to reach the market due to preclinical study results, regulatory approvals, manufacturing costs, or proprietary rights of others.
• The company will rely upon licensed patents to protect its technology and may be unable to obtain or protect such intellectual property rights, or may be liable for infringing upon the intellectual property rights of others.
• The company is dependent upon TheraCour for the rights to develop the products it intends to sell, and its license agreements with TheraCour require that TheraCour is the sole developer and supplier of licensed products.
• The expiration or loss of patent protection may adversely affect future revenues and operating earnings.
• The company lacks suitable facilities for clinical testing and relies on third parties, introducing risks of delays or termination if these parties fail to perform.
• The company has limited manufacturing experience and does not own or lease facilities suitable for cGMP manufacture of large commercial quantities.
• Efforts of government and third-party payers to contain or reduce the costs of health care may adversely affect revenues even if an FDA-approved drug is developed.
• General securities market uncertainties resulting from international turmoil, inflation, and policy changes may limit the company's ability to raise required capital.
• Failure to meet NYSE American continued listing standards could result in delisting, limiting investor transactions and subjecting the company to additional trading restrictions.
• The company is subject to periodic reporting requirements of the Securities Exchange Act of 1934, incurring audit and legal fees that reduce profitability.
• The company may be exposed to potential risks under Section 404 of the Sarbanes-Oxley Act of 2002, impacting financial reporting reliability.
• Common stock may be considered a penny stock, making it difficult to sell and subject to additional trading restrictions.
• The company's stock price may be volatile, and investment in common stock could suffer a decline in value.
• There is a risk of market fraud, particularly in the penny stock market, which could increase stock price volatility.
• Registration of a significant amount of outstanding restricted stock may have a negative effect on the trading price.
• The company does not intend to pay any cash dividends in the foreseeable future, so any return on investment must come from increases in stock value.
• Issuance of additional equity shares to fund operational requirements would dilute share ownership and may adversely affect the market price.

Future Outlook

The company anticipates completing and submitting the final report for the NV-387 Phase Ia/Ib clinical trial soon. It plans to initiate a Phase II clinical trial for NV-387 as a treatment for MPox in DRC and another adaptive, basket-type Phase II clinical trial for viral acute and severe-acute respiratory infections (ARI/SARI) in India, aiming to generate data against multiple respiratory viruses including Influenza, RSV, and Coronaviruses. The company intends to seek Orphan Drug Designations for NV-387 for MPox, Smallpox, and Measles in the USA, and pursue non-dilutive funding for biodefense applications like Smallpox. Further development of NV-387 for pediatric RSV and Influenza treatments is planned once sufficient resources become available. The HerpeCide and HIVCide programs are expected to be re-engaged when resources permit. Management believes achieving these milestones will enhance its ability to raise additional funds and attract partnerships, potentially leading to exponential growth and rapid clinical development of additional candidates.

Management Comments

• We anticipate its submission to the regulatory agency in India soon.
• We believe NV-387 could revolutionize the treatment of viral infections the same way that penicillin revolutionized the treatment of bacterial infections.
• We believe that a safe and effective antiviral drug, when approved, with an extensive broad-spectrum activity across multiple, distinct, virus families is an unmet medical need.
• We believe that the NV-HHV-1 skin cream, when approved, can also be additionally indicated to treat HSV-1 cold sores and HSV-2 genital ulcers based on successful animal studies.
• We believe it is possible that NV-HIV-1 itself or a further modified form to include mimicking the CCR5 portion, could lead to a drug that is close to a cure for HIV infection.
• Having such integrated facility available enabled us to develop the NV-CoV-2 COVID drug (that contains the active pharmaceutical ingredient NV-387) from concept to completion of safety/pharmacology studies required for clinical trials within a matter of just one year.
• We believe that a safe and effective drug against Smallpox that would be of interest to the US Government as well as other international agencies.
• We believe that positive data, if the Phase II of NV-387 for treating MPox is successful, would go a long way towards the goal of approval of NV-387 for Smallpox as well, because MPox is an orthopoxvirus closely related to the Variola virus that causes Smallpox.
• We believe our animal model study results for the lethal orthopoxvirus infection via the dermal infection route as well as via direct inhalation of viral particles into lungs are sufficiently robust to generate confidence to anticipate positive outcome from the proposed Phase II clinical trial of NV-387 for the treatment of MPox.
• We believe that NV-387 would be able to go through regulatory clinical trials for Influenza viruses successfully and would be able to receive regulatory approvals.
• We believe that NV-387 would be able to go through regulatory clinical trials for RSV successfully and would be able to receive regulatory approvals.
• We believe that this data provides sufficient rationale for a physician to use NV-387 for the treatment of a case of measles under a FDA pathway called the Physician-Initiated IND.
• We believe we have developed several assets worthy of partnering for further regulatory development and commercialization.
• We believe this is now common knowledge after the COVID pandemic.
• We believe that our unique host-mimetic approach would result in a nanoviricide drug that a virus cannot escape even as it changes in the field...
• We believe that our approach for improved drug safety is validated by the demonstration of strong relevant results in animal studies of NV-387 for safety and tolerability.
• We believe that this level of effective bioavailability is excellent and it would permit development of NV-387 as an oral drug for treatment of RSV infection.
• These lung histo-pathology results in conjunction with the complete survival of NV-387 orally treated animals support our belief that NV-387 oral treatment led to complete cure of the lethal RSV infection in mice in this animal trial.
• We believe that these results suggest that NV-387 promises to be effective against the bird flu influenza virus H5N1 (and other similar H5Nx viruses) as well.
• Thus NV-387 with its broad spectrum and unlikely escape of virus is expected to become an important weapon in the treatment of influenza virus infections.
• Thus we believe that NV-387 has a high likelihood of success as a treatment for MPox in the Phase II clinical trial.
• Further, we believe that NV-387 is a strong potential candidate for approval as a treatment for smallpox under the US FDA Animal Rule, based the animal study data.
• Thus, we believe NV-387 alone may propel NanoViricides towards great success in a near-term horizon.
• We believe that with the human clinical trials of NV-387, we will be able to accumulate the evidence of antiviral effectiveness in human infections, in addition to human safety and effectiveness, that would help us achieve meaningful partnerships with Big Pharma.
• We believe that as we achieve proof of principle in human studies, we will be able to attract substantially greater market valuation and investor funding for further progress of these drugs towards approval and commercialization.
• We believe that once we have revenues from commercialization of our first drug or from partnership, we will be able to engage in further speeding up the development of our other programs.
• Based on our pre-clinical study data, we believe that we have a very high probability that NV-387 would be demonstrated to be a highly effective and safe drug for the treatment of MPox in the Phase II clinical trial, and also for the treatment of RSV, Influenza, Coronaviruses, hMPV, and other respiratory viruses in the ensuing Phase II Viral ARI/SARI clinical trial.
• We further believe NV-387 could be a revolutionary drug for the treatment of pediatric RSV infections, based on our data that NV-387 treatment appears to have cured mice of lethal lung RSV infection, with no lung damage.

Industry Context

The biopharmaceutical industry is characterized by rapid technological developments, high competition, and significant regulatory hurdles. NanoViricides' nanoviricide platform aims to address a critical unmet need in antiviral therapeutics: the rapid evolution of viruses that escape traditional approaches like vaccines, antibodies, and small chemical drugs. The company's broad-spectrum approach with NV-387, targeting common host attachment receptors, positions it uniquely against the "one-drug-one-bug" paradigm prevalent in current antiviral development. The increasing global outbreaks of diseases like Measles and the ongoing threat of MPox and potential pandemics (e.g., Bird Flu) highlight the urgent need for broad-spectrum, escape-resistant antivirals. The biodefense market, particularly for Smallpox, also presents a significant opportunity for government funding and stockpiling, especially given the limitations and failures of existing approved drugs like tecovirimat and brincidofovir. The company's integrated development and manufacturing capabilities are a notable advantage in an industry often reliant on external contract organizations.

Comparison to Industry Standards

• NV-387 is positioned as a broad-spectrum, direct-acting antiviral with significant safety and tolerability benefits, unlike current broad-spectrum antivirals such as Remdesivir, Ribavirin, and Cidofovir that suffer from extensive dose-limiting toxicities and limitations on eligible patient populations.
• Nanoviricides are designed to be "host-mimetic," making virus escape unlikely even with mutations, a key advantage over traditional vaccines and antibodies which are readily escaped by evolving viruses (e.g., COVID-19 variants). They also do not require a healthy immune system, making them applicable for all patient populations, including immune-compromised individuals, unlike vaccines and antibodies.
• In lethal lung RSV infection animal models, oral NV-387 led to complete survival and no lung damage, significantly outperforming ribavirin, which is highly toxic and used only as a last resort.
• In lethal lung Influenza A/H3N2 animal models, oral NV-387 resulted in nearly 2.5 to 3 times greater survival improvement compared to three approved drugs: oseltamivir (Tamiflu, Roche), baloxavir (Xofluza, Shionogi, Roche), and peramivir (Rapivab, BioCryst). Existing influenza drugs are also susceptible to virus escape by simple mutations, a vulnerability NV-387 aims to overcome.
• In lethal mousepox animal models (a standard model for Smallpox and MPox), oral NV-387 matched the activity of approved tecovirimat (TPOXX, SIGA). A combination of NV-387 and tecovirimat showed significantly better survival (112-138% increase) than either drug alone. Tecovirimat has a low barrier to virus escape (single point mutation), and brincidofovir (TEMBREXA, Emergent Bio) carries a Black Box Warning due to increased mortality in unrelated trials, diarrhea (40% patients), liver issues, carcinogenicity, and reproductive harm. Tecovirimat also failed to show superiority over placebo in recent MPox clinical trials (PALM007, UNITY). NV-387's safety profile (no adverse events in Phase I) and broad-spectrum nature address key limitations of these competitors.
• There is no approved treatment for measles. Ribavirin, a highly toxic drug, is recommended by CDC for severe hospitalized cases but is not approved. NV-387 showed significant survival increase (130%) in a lethal measles virus lung infection humanized mouse model, indicating a potential unmet medical need.
• Unlike most other nanomedicines that are limited to injectable routes, NV-387 demonstrated strong oral activity in animal studies, distinguishing the company's technology.
• NanoViricides owns fully integrated cGMP-capable manufacturing facilities, a rare asset for a small pharmaceutical innovator, which helps control quality, speed development, and save costs compared to relying solely on external Contract Manufacturing Organizations (CMOs).

Management Changes

Corporate Governance

Legal Proceedings

• No pending legal proceedings against the company that are believed to have a material adverse effect on its business, financial position, results of operations, or liquidity.
• No action, suit, or proceeding has been threatened against the company that is believed to have a material adverse effect.

Related Party Transactions

• NanoViricides has exclusive, worldwide licenses from TheraCour Pharma, Inc. for various viral diseases (HIV/AIDS, Influenza, Herpes Simplex, Hepatitis C, Hepatitis B, Rabies, Dengue, Japanese Encephalitis, West Nile, viral Conjunctivitis, Ocular Herpes, Ebola/Marburg, VZV, Coronaviruses).
• TheraCour performs R&D work for NanoViricides, charging costs (direct and indirect) plus a development fee (no more than 30% of certain direct costs).
• NanoViricides pays TheraCour 15% of net sales from licensed products and sublicensed products upon commercialization.
• Development fees and other costs charged by TheraCour were approximately $2,490,000 for FY2025 and $2,550,000 for FY2024.
• Accounts payable to TheraCour were approximately $584,000 at June 30, 2025.
• In FY2023, a $1,500,000 cash milestone payment for NV-387 Phase I initiation was converted into 331,859 shares of Series A Preferred Stock, and accrued interest of $49,808 was cancelled by TheraCour.
• An amendment to the COVID License Agreement (Feb 12, 2024) stipulates that future cash milestone payments are only payable upon NanoViricides having sufficient revenue, with no more than 50% of recognized revenue applied to such payments. This provision was codified for all present and future license agreements in a September 23, 2024 MOU.
• TheraCour retains exclusive rights to develop and manufacture licensed products for NanoViricides.
• Dr. Anil Diwan, NanoViricides' President and Executive Chairman, owns approximately 90% of TheraCour's capital stock. TheraCour owns 470,961 shares of NanoViricides common stock and 681,859 shares of Series A preferred stock as of June 30, 2025.
• NanoViricides granted Karveer Meditech Pvt. Ltd. (KMPL) a limited, non-transferable, exclusive license for use, sale, or offer of sale in India of NV-CoV-2 and NV-CoV-2-R for COVID-19 treatment.
• KMPL sponsors human clinical trials in India and acts as clinical trials manager, with NanoViricides reimbursing KMPL for all direct and indirect costs plus a 30% management fee.
• Upon commercial sales, KMPL will pay NanoViricides a royalty of 70% of final invoiced sales less costs to unaffiliated third parties.
• Clinical trial costs incurred to KMPL were approximately $9,932 for FY2025 and $442,845 for FY2024.
• Accounts payable to KMPL were $237,367 at June 30, 2025.
• Dr. Anil Diwan is a passive investor and advisor in KMPL, which is owned by the Diwan family.
• Dr. Anil Diwan provided a standby Line of Credit to the company, initially $2 million (Nov 13, 2023), increased to $3 million (Sept 23, 2024), and extended maturity to March 31, 2027 (July 1, 2025). Undrawn as of June 30, 2025.
• Dr. Anil Diwan's employment agreement was extended to June 30, 2026, with an annual base salary of $400,000 and a grant of 10,204 shares of Series A preferred stock.
• Meeta Vyas, Chief Financial Officer and wife of Dr. Anil Diwan, had her CFO agreement extended to June 30, 2026, with a base compensation of $10,800 per month.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing equity-based financing (ATM offerings) and a major risk to investment value due to substantial doubt about the company's going concern status. Continued operating losses and accumulated deficit erode shareholder equity. Potential for stock price volatility and penny stock designation.
• Shareholders could see significant returns if drug candidates achieve regulatory approval and commercialization, especially given the large target markets and broad-spectrum nature of NV-387. Strong intellectual property protection and integrated manufacturing facilities could create long-term value.
• Employees may face job security concerns and limited growth opportunities due to staffing constraints and financial limitations.
• Employees benefit from continued employment and compensation, including stock-based awards for executives, tied to company success.
• Future customers could benefit from revolutionary, safe, and effective broad-spectrum antiviral treatments for a wide range of viral infections, addressing significant unmet medical needs. Oral formulations and multiple routes of administration could improve patient access and compliance.
• Suppliers and collaborators may face risks related to the company's financial constraints and going concern doubt, potentially impacting payment for services or continuation of collaborations.
• Creditors face elevated credit risk due to the "going concern" doubt and accumulated deficit. The line of credit from Dr. Anil Diwan is collateralized, offering some security for that specific debt.

Next Steps

• Complete and submit the final Clinical Study Report (CSR) for the NV-387 Phase Ia/Ib clinical trial to the Indian regulatory body (CDSCO).
• File the Clinical Trial Application (CTA) for the Phase II NV-387-MPox clinical trial to ACOREP in DRC.
• Initiate the Phase II NV-387-MPox Clinical Trial.
• Obtain top-line effectiveness and safety/tolerability data from the Phase II NV-387-MPox Clinical Trial.
• Complete the in-hospital treatment part of the Phase II NV-387-MPox Clinical Trial.
• Close the Phase II NV-387-MPox Clinical Trial, perform data analysis, and prepare initial reports.
• File the Clinical Trial Application (CTA) for the Phase II NV-387-ARI/SARI clinical trial in India.
• Initiate the Phase II NV-387-ARI/SARI Clinical Trial.
• Obtain top-line effectiveness and safety/tolerability data from the Phase II NV-387-ARI/SARI Clinical Trial.
• Potentially complete the in-hospital treatment part of the Phase II NV-387-MPox Clinical Trial.
• File for Orphan Drug Designation for NV-387 as a treatment for MPox in the USA.
• File for Orphan Drug Designation for NV-387 as a treatment for Smallpox in the USA.
• File for Orphan Drug Designation for NV-387 as a treatment for Measles in the USA.
• File Pre-IND Application for NV-387 as a treatment for MPox in the USA.
• File Pre-IND Application for NV-387 as a treatment for Smallpox in the USA.
• File Pre-IND Application for NV-387 as a treatment for Measles in the USA.
• File a Pre-IND application for RSV treatment for Phase II human clinical trials for NV-387 in the USA.
• Complete an effective clinical trial plan for the Shingles drug candidate (NV-HHV-1) to re-engage human clinical trials for the shingles treatment program.
• Actively seek partnerships and out-licensing opportunities for drug candidates and platform technology.
• Pursue non-dilutive funding (grants, contracts) for biodefense and pandemic preparedness objectives.
• Continue to finance efforts using equity-based financing and debt, as needed.
• Investigate the appropriate regulatory route for approval of NV-387 to treat Measles.
• Re-engage HerpeCide and HIVCide programs when sufficient resources become available.
• Bring some regulatory affairs capabilities in-house to speed up processes.

Key Dates

Recommendation

Despite promising preclinical and Phase I clinical data for NV-387 and a broad pipeline, NanoViricides, Inc. faces severe financial distress. The company explicitly states "substantial doubt exists about the Company's ability to continue as a going concern" due to recurring net losses ($9.47 million in FY2025), a massive accumulated deficit ($148.84 million), and insufficient cash ($1.56 million at FY2025 end, even with post-period ATM sales). Operating cash burn is increasing ($8.48 million in FY2025). While the founder's line of credit offers some buffer, it's not a long-term solution. The company's reliance on dilutive equity financing will likely continue, further eroding shareholder value. The significant risks associated with drug development (long timelines, high costs, regulatory uncertainty, competition) are amplified by the company's precarious financial state and staffing constraints. Given the high probability of further dilution, potential for operational disruptions due to funding shortfalls, and the explicit going concern warning, a seasoned investor would likely recommend selling to mitigate risk.

Keywords

Nanoviricides, Antiviral drugs, Drug development, Clinical stage, NV-387, MPox, Smallpox, RSV, Influenza, Coronaviruses, Herpesviruses, HIV, Biodefense, Orphan Drug Designation, Phase II clinical trials, Nanomedicine, Biopharmaceutical, SEC filing, 10-K, TheraCour Pharma, Karveer Meditech, Going concern, Equity financing, Intellectual property